S 10 IS
107th CONGRESS
1st Session
S. 10
To amend title XVIII of the Social Security Act to provide coverage
of outpatient prescription drugs under the medicare program.
IN THE SENATE OF THE UNITED STATES
January 22, 2001
Mr. DASCHLE (for himself, Mr. BAUCUS, Mr. GRAHAM, Mr. KENNEDY, Mr. AKAKA, Mr.
BIDEN, Mr. BINGAMAN, Mrs. BOXER, Mr. BYRD, Mrs. CARNAHAN, Mr. CLELAND, Mrs.
CLINTON, Mr. CORZINE, Mr. DAYTON, Mr. DODD, Mr. DORGAN, Mr. DURBIN, Mr.
HOLLINGS, Mr. INOUYE, Mr. JOHNSON, Mr. KERRY, Mr. LEAHY, Mr. LEVIN, Mrs.
LINCOLN, Ms. MIKULSKI, Mrs. MURRAY, Mr. NELSON of Florida, Mr. REED, Mr. REID,
Mr. ROCKEFELLER, Mr. SARBANES, and Mr. SCHUMER) introduced the following bill;
which was read twice and referred to the Committee on Finance
A BILL
To amend title XVIII of the Social Security Act to provide coverage
of outpatient prescription drugs under the medicare program.
Be it enacted by the Senate and House of Representatives of the United
States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
(a) SHORT TITLE- This Act may be cited as the `Medicare Prescription Drug
Coverage Act of 2001'.
(b) TABLE OF CONTENTS- The table of contents of this Act is as follows:
Sec. 1. Short title; table of contents.
Sec. 3. Medicare outpatient prescription drug benefit program.
`Part D--Outpatient Prescription Drug Benefit Program
`Sec. 1860. Definitions.
`Subpart 1--Establishment of Outpatient Prescription Drug Benefit
Program
`Sec. 1860A. Establishment of outpatient prescription drug benefit
program.
`Sec. 1860B. Enrollment.
`Sec. 1860C. Providing information to beneficiaries.
`Sec. 1860D. Premiums.
`Sec. 1860E. Cost-sharing.
`Sec. 1860F. Selection of entities to provide outpatient drug
benefit.
`Sec. 1860G. Conditions for awarding contract.
`Sec. 1860H. Payments.
`Sec. 1860I. Employer incentive program for employment-based retiree
drug coverage.
`Sec. 1860J. Procedures for partial year implementation.
`Sec. 1860K. Appropriations.
`Subpart 2--Medicare Pharmacy and Therapeutics (P&T) Advisory
Committee
`Sec. 1860M. Medicare Pharmacy and Therapeutics (P&T) Advisory
Committee.'.
Sec. 4. Part D benefits under Medicare+Choice plans.
Sec. 5. Exclusion of part D costs from determination of part B monthly
premium.
Sec. 6. Additional assistance for low-income beneficiaries.
Sec. 7. Medigap revisions.
Sec. 8. Comprehensive immunosuppressive drug coverage for transplant
patients.
Sec. 9. HHS studies and report to Congress regarding outpatient
prescription drug benefit program.
Sec. 10. GAO study and biennial reports on competition and
savings.
Sec. 11. MedPAC study and annual reports on the pharmaceutical market,
pharmacies, and beneficiary access.
SEC. 2. FINDINGS.
Congress makes the following findings:
(1) Prescription drug coverage was not a standard part of health
insurance when the medicare program under title XVIII of the Social Security
Act was enacted in 1965. Since 1965, however, drug coverage has become a key
component of most private and public health insurance coverage, except for
the medicare program.
(2) At least 2/3 of medicare beneficiaries have unreliable, inadequate,
or no drug coverage at all.
(3) Seniors who do not have drug coverage typically pay 15 percent more
for prescription drugs than individuals that have such coverage pay for such
drugs, and often pay 2 times the best available price for such drugs.
(4) Although many medicare beneficiaries who lack prescription drug
coverage have low incomes, more than 1/2 of such beneficiaries have incomes
greater than 150 percent of the poverty line.
(5) The number of private firms offering retiree health coverage is
declining.
(6) The premiums for medicare supplemental policies (medigap policies)
that provide prescription drug coverage are too expensive for most medicare
beneficiaries and are highest for older senior citizens who need
prescription drug coverage the most and typically have the lowest
incomes.
(7) The management of a medicare prescription drug benefit should mirror
the practices employed by private entities in delivering prescription drugs.
Discounts should be achieved through competition.
(8) All medicare beneficiaries should have access to a voluntary,
reliable, affordable outpatient drug benefit as part of the medicare program
that assists with the high cost of prescription drugs and protects them
against excessive out-of-pocket costs.
(9) The addition of a medicare drug benefit should be consistent with an
overall plan to strengthen and modernize the medicare program.
SEC. 3. MEDICARE OUTPATIENT PRESCRIPTION DRUG BENEFIT PROGRAM.
(a) ESTABLISHMENT- Title XVIII of the Social Security Act (42 U.S.C. 1395
et seq.) is amended by redesignating part D as part E and by inserting after
part C the following new part:
`Part D--Outpatient Prescription Drug Benefit Program
`DEFINITIONS
`SEC. 1860. In this part:
`(1) COVERED OUTPATIENT DRUG-
`(A) IN GENERAL- Except as provided in subparagraph (B), the term
`covered outpatient drug' means any of the following products:
`(i) A drug which may be dispensed only upon prescription,
and--
`(I) which is approved for safety and effectiveness as a
prescription drug under section 505 of the Federal Food, Drug, and
Cosmetic Act;
`(II)(aa) which was commercially used or sold in the United States
before the date of enactment of the Drug Amendments of 1962 or which
is identical, similar, or related (within the meaning of section
310.6(b)(1) of title 21 of the Code of Federal Regulations) to such a
drug, and (bb) which has not been the subject of a final determination
by the Secretary that it is a `new drug' (within the meaning of
section 201(p) of the Federal Food, Drug, and Cosmetic Act) or an
action brought by the Secretary under section 301, 302(a), or 304(a)
of such Act to enforce section 502(f) or 505(a) of such Act;
or
`(III)(aa) which is described in section 107(c)(3) of the Drug
Amendments of 1962 and for which the Secretary has determined there is
a compelling justification for its medical need, or is identical,
similar, or related (within the meaning of section 310.6(b)(1) of
title 21 of the Code of Federal Regulations) to such a drug, and (bb)
for which the Secretary has not issued a notice of an opportunity for
a hearing under section 505(e) of the Federal Food, Drug, and Cosmetic
Act on a proposed order of the Secretary to withdraw approval of an
application for such drug under such section because the Secretary has
determined that the drug is less than effective for all conditions of
use prescribed, recommended, or suggested in its
labeling.
`(ii) A biological product which--
`(I) may only be dispensed upon prescription;
`(II) is licensed under section 351 of the Public Health Service
Act; and
`(III) is produced at an establishment licensed under such section
to produce such product.
`(iii) Insulin approved under appropriate Federal law, including
needles, syringes, and disposable pumps for the administration of such
insulin.
`(iv) A prescribed drug or biological product that would meet the
requirements of clause (i) or (ii) but that it is available
over-the-counter in addition to being available upon
prescription.
`(B) EXCLUSION- The term `covered outpatient drug' does not include
any product--
`(i) except as provided in subparagraph (A)(iv), which may be
distributed to individuals without a prescription;
`(ii) that is covered under part A or B (unless coverage of such
product is not available because benefits under part A or B have been
exhausted); or
`(iii) except for agents used to promote smoking cessation, for
which coverage may be excluded or restricted under section
1927(d)(2).
`(2) ELIGIBLE BENEFICIARY- The term `eligible beneficiary' means an
individual that is entitled to benefits under part A or enrolled under part
B.
`(3) ELIGIBLE ENTITY- The term `eligible entity' means any entity that
the Secretary determines to be appropriate to provide eligible beneficiaries
with covered outpatient drugs under a contract entered into under this part,
including--
`(A) a pharmacy benefit management company;
`(B) a retail pharmacy delivery system;
`(C) a health plan or insurer;
`(D) a State (through mechanisms established under a State plan under
title XIX);
`(E) any other entity approved by the Secretary; or
`(F) any combination of the entities described in subparagraphs (A)
through (E) if the Secretary determines that such combination--
`(i) increases the scope or efficiency of the provision of benefits
under this part; and
`(ii) is not anticompetitive.
`Subpart 1--Establishment of Outpatient Prescription Drug Benefit
Program
`ESTABLISHMENT OF OUTPATIENT PRESCRIPTION DRUG BENEFIT PROGRAM
`SEC. 1860A. (a) PROVISION OF BENEFIT- Beginning on the date that is 1
year after the date of enactment of this Act, the Secretary shall provide for
an outpatient prescription drug benefit program under which an eligible
beneficiary shall be provided covered outpatient drugs.
`(b) VOLUNTARY NATURE OF PROGRAM- Nothing in this part shall be construed
as requiring an eligible beneficiary to enroll in the program established
under this part.
`(c) SCOPE OF BENEFITS- The program established under this part shall
provide for coverage of all therapeutic classes of covered outpatient
drugs.
`(d) FINANCING- The costs of providing benefits under this part shall be
payable from the Federal Supplementary Medical Insurance Trust Fund
established under section 1841.
`ENROLLMENT
`SEC. 1860B. (a) ENROLLMENT UNDER PART D-
`(1) ESTABLISHMENT OF PROCESS-
`(A) IN GENERAL- The Secretary shall establish a process through which
an eligible beneficiary (including an eligible beneficiary enrolled in a
Medicare+Choice plan offered by a Medicare+Choice organization) may make
an election to enroll under this part. Such process shall be similar to
the process for enrollment in part B under section 1837.
`(B) REQUIREMENT OF ENROLLMENT- An eligible beneficiary must enroll
under this part in order to be eligible to receive covered outpatient
drugs under this title.
`(2) ENROLLMENT PROCEDURES-
`(A) LATE ENROLLMENT PENALTY-
`(i) IN GENERAL- Subject to the succeeding provisions of this
subparagraph, in the case of an eligible beneficiary whose coverage
period under this part began pursuant to an enrollment after the
beneficiary's initial enrollment period under part B (determined
pursuant to section 1837(d)) and not pursuant to the open enrollment
period described in subparagraph (B), the Secretary shall establish
procedures for increasing the amount of the monthly premium under
section 1860D applicable to such beneficiary--
`(I) by an amount that is equal to 10 percent of such premium for
each full 12-month period (in the same continuous period of
eligibility) in which the eligible beneficiary could have been
enrolled under this part but was not so enrolled; or
`(II) if determined appropriate by the Secretary, by an amount
that the Secretary determines is actuarily sound for each such
period.
`(ii) PERIODS TAKEN INTO ACCOUNT- For purposes of calculating any
12-month period under clause (i), there shall be taken into
account--
`(I) the months which elapsed between the close of the eligible
beneficiary's initial enrollment period and the close of the
enrollment period in which the beneficiary enrolled;
and
`(II) in the case of an eligible beneficiary who reenrolls under
this part, the months which elapsed between the date of termination of
a previous coverage period and the close of the enrollment period in
which the beneficiary reenrolled.
`(iii) PERIODS NOT TAKEN INTO ACCOUNT-
`(I) IN GENERAL- For purposes of calculating any 12-month period
under clause (i), subject to subclause (II), there shall not be taken
into account months for which the eligible beneficiary can demonstrate
that the beneficiary was covered under a group health plan, including
a qualified retiree prescription drug plan (as defined in section
1860I(e)(3)) for which an incentive payment was paid under section
1860I, that provides coverage of the cost of prescription drugs whose
actuarial value (as defined by the Secretary) to the beneficiary
equals or exceeds the actuarial value of the benefits provided to an
individual enrolled in the outpatient prescription drug benefit
program under this part.
`(II) APPLICATION- This clause shall only apply with respect to a
coverage period the enrollment for which occurs before the end of the
60-day period that begins on the first day of the month which includes
the date on which the plan terminates, ceases to provide, or reduces
the value of the prescription drug coverage under such plan to below
the value of the coverage provided under the program under this
part.
`(iv) PERIODS TREATED SEPARATELY- Any increase in an eligible
beneficiary's monthly premium under clause (i) with respect to a
particular continuous period of eligibility shall not be applicable with
respect to any other continuous period of eligibility which the
beneficiary may have.
`(v) CONTINUOUS PERIOD OF ELIGIBILITY-
`(I) IN GENERAL- Subject to subclause (II), for purposes of this
subparagraph, an eligible beneficiary's
`continuous period of eligibility' is the period that begins with the first
day on which the beneficiary is eligible to enroll under section 1836 and ends
with the beneficiary's death.
`(II) SEPARATE PERIOD- Any period during all of which an eligible
beneficiary satisfied paragraph (1) of section 1836 and which
terminated in or before the month preceding the month in which the
beneficiary attained age 65 shall be a separate `continuous period of
eligibility' with respect to the beneficiary (and each such period
which terminates shall be deemed not to have existed for purposes of
subsequently applying this subparagraph).
`(B) OPEN ENROLLMENT PERIOD FOR CURRENT BENEFICIARIES IN WHICH LATE
ENROLLMENT PROCEDURES DO NOT APPLY- The Secretary shall establish an
applicable period, which shall begin on the date on which the Secretary
first begins to accept elections for enrollment under this part, during
which any eligible beneficiary may enroll under this part without the
application of the late enrollment procedures established under
subparagraph (A)(i).
`(A) IN GENERAL- Except as provided in subparagraph (B), an eligible
beneficiary's coverage under the program under this part shall be
effective for the period provided in section 1838, as if that section
applied to the program under this part.
`(B) OPEN ENROLLMENT- An eligible beneficiary who enrolls under the
program under this part pursuant to paragraph (2)(B) shall be entitled to
the benefits under this part beginning on the first day of the month
following the month in which such enrollment occurs.
`(C) LIMITATION- Coverage under this part shall not begin prior to the
date that is 1 year after the date of enactment of this Act.
`(4) PART D COVERAGE TERMINATED BY TERMINATION OF COVERAGE UNDER PARTS A
AND B-
`(A) IN GENERAL- In addition to the causes of termination specified in
section 1838, the Secretary shall terminate an individual's coverage under
this part if the individual is no longer enrolled in either part A or part
B.
`(B) EFFECTIVE DATE- The termination described in subparagraph (A)
shall be effective on the effective date of termination of coverage under
part A or (if later) under part B.
`(b) ENROLLMENT WITH ELIGIBLE ENTITY-
`(A) IN GENERAL- The Secretary shall establish a process through which
an eligible beneficiary who is enrolled under this part but not enrolled
in a Medicare+Choice plan offered by a Medicare+Choice organization shall
make an annual election to enroll with any eligible entity that has been
awarded a contract under this part and serves the geographic area in which
the beneficiary resides.
`(B) RULES- In establishing the process under subparagraph (A), the
Secretary shall use rules similar to the rules for enrollment and
disenrollment with a Medicare+Choice plan under section 1851 (including
special election periods under subsection (e)(4) of such
section).
`(2) MEDICARE+CHOICE ENROLLEES- An eligible beneficiary who is enrolled
under this part and enrolled in a Medicare+Choice plan offered by a
Medicare+Choice organization shall receive coverage of covered outpatient
drugs under this part through such plan.
`(c) FIRST ENROLLMENT PERIOD- The processes developed under subsections
(a) and (b) shall ensure that eligible beneficiaries are permitted to enroll
under this part and with an eligible entity prior to the date that is 1 year
after the date of enactment of this Act, in order to ensure that coverage
under this part is effective as of such date.
`PROVIDING INFORMATION TO BENEFICIARIES
`SEC. 1860C. (a) ACTIVITIES-
`(1) IN GENERAL- The Secretary shall conduct activities that are
designed to broadly disseminate information to eligible beneficiaries (and
prospective eligible beneficiaries) regarding the coverage provided under
this part.
`(2) SPECIAL RULE FOR FIRST ENROLLMENT UNDER THE PROGRAM- To the extent
practicable, the activities described in paragraph (1) shall ensure that
eligible beneficiaries are provided with such information at least 30 days
prior to the first enrollment period described in section 1860B(c).
`(1) IN GENERAL- The activities described in subsection (a)
shall--
`(A) be similar to the activities performed by the Secretary under
section 1851(d);
`(B) be coordinated with the activities performed by the Secretary
under such section and under section 1804; and
`(C) provide for the dissemination of information comparing the
eligible entities that are available to eligible beneficiaries residing in
an area under this part.
`(2) COMPARATIVE INFORMATION- The comparative information described in
paragraph (1)(B) shall include the following:
`(A) BENEFITS- A comparison of the benefits provided by each eligible
entity, including a comparison of the pharmacy networks used by each
eligible entity and the formularies and appeals processes implemented by
each entity.
`(B) QUALITY AND PERFORMANCE- To the extent available, the quality and
performance of each eligible entity.
`(C) BENEFICIARY COSTS- The cost-sharing required of eligible
beneficiaries enrolled in each eligible entity.
`(D) CONSUMER SATISFACTION SURVEYS- To the extent available, the
results of consumer satisfaction surveys regarding each eligible
entity.
`(E) ADDITIONAL INFORMATION- Such additional information as the
Secretary may prescribe.
`(3) INFORMATION STANDARDS- The Secretary shall develop standards to
ensure that the information provided to eligible beneficiaries under this
part is complete, accurate, and uniform.
`(c) USE OF MEDICARE CONSUMER COALITIONS TO PROVIDE INFORMATION-
`(1) IN GENERAL- The Secretary may contract with Medicare Consumer
Coalitions to conduct the informational activities--
`(B) under section 1851(d); and
`(2) SELECTION OF COALITIONS- If the Secretary determines the use of
Medicare Consumer Coalitions to be appropriate, the Secretary shall--
`(A) develop and disseminate, in such areas as the Secretary
determines appropriate, a request for proposals for Medicare Consumer
Coalitions to contract with the Secretary in order to conduct any of the
informational activities described in paragraph (1); and
`(B) select a proposal of a Medicare Consumer Coalition to conduct the
informational activities in each such area, with a preference for broad
participation by organizations with experience in providing information to
beneficiaries under this title.
`(3) PAYMENT TO MEDICARE CONSUMER COALITIONS- The Secretary shall make
payments to Medicare Consumer Coalitions contracting under this subsection
in such amounts and in such manner as the Secretary determines
appropriate.
`(4) AUTHORIZATION OF APPROPRIATIONS- There are authorized to be
appropriated to the Secretary such sums as may be necessary to contract with
Medicare Consumer Coalitions under this section.
`(5) MEDICARE CONSUMER COALITION DEFINED- In this subsection, the term
`Medicare Consumer Coalition' means an entity that is a nonprofit
organization operated under the direction of a board of directors that is
primarily composed of beneficiaries under this title.
`PREMIUMS
`SEC. 1860D. (a) ANNUAL ESTABLISHMENT OF MONTHLY PREMIUM RATES-
`(1) PREMIUM- The Secretary shall, during September of each year
(beginning with the first September after the day that is 1 year after the
date of enactment of the Medicare Prescription Drug Coverage Act of 2001),
determine and promulgate a monthly premium rate for the succeeding year in
accordance with the provisions of this subsection.
`(2) ACTUARIAL DETERMINATIONS-
`(A) DETERMINATION OF ANNUAL BENEFIT AND ADMINISTRATIVE COSTS- The
Secretary shall estimate annually for the succeeding year the amount equal
to the total of the benefits and administrative costs that will be payable
from the Federal Supplementary Medical Insurance Trust Fund for providing
covered outpatient drugs in such calendar year with respect to enrollees
in the program under this part.
`(B) DETERMINATION OF MONTHLY PREMIUM RATES-
`(i) IN GENERAL- The Secretary shall determine the monthly premium
rate with respect to such enrollees for such succeeding year, which
shall be 1/12 of the applicable percent of the amount determined under
subparagraph (A), divided by the total number of such enrollees, and
rounded (if such rate is not a multiple of 10 cents) to the nearest
multiple of 10 cents.
`(ii) DEFINITION OF APPLICABLE PERCENT- For purposes of clause (i),
the term `applicable percent' means--
`(I) 45 percent, in the case of premiums paid by an eligible
beneficiary enrolled in the program under this part;
and
`(II) 66.66 percent, in the case of premiums paid for such a
beneficiary by an employer (as defined in section 1860I(e)(2)) that
the beneficiary formerly worked for.
`(3) PUBLICATION OF ASSUMPTIONS- The Secretary shall publish, together
with the promulgation of the monthly premium rates for the succeeding year,
a statement setting forth the actuarial assumptions and bases employed in
arriving at the amounts and rates determined under paragraphs (1) and
(2).
`(b) COLLECTION OF PREMIUM- The monthly premium applicable to an eligible
beneficiary under this part shall be collected and credited to the Federal
Supplementary Medical Insurance Trust Fund in the same manner as the monthly
premium determined under section 1839 is collected and credited to such Trust
Fund under section 1840.
`COST-SHARING
`SEC. 1860E. (a) DEDUCTIBLE-
`(1) IN GENERAL- Subject to paragraph (2), no payments shall be made
under this part on behalf of an eligible beneficiary until the beneficiary
has met a $250 deductible.
`(2) WAIVER OF DEDUCTIBLE FOR GENERIC DRUGS-
`(A) IN GENERAL- An eligible entity may provide that generic drugs are
not subject to the deductible described in paragraph (1) if the Secretary
determines that the waiver of the deductible--
`(i) is tied to the performance measures and other incentives
applicable to the entity pursuant to section 1860H(a); and
`(ii) will not result in an increase in the expenditures made from
the Federal Supplementary Medical Insurance Trust Fund.
`(B) CREDIT FOR AMOUNTS PAID- If the deductible is waived pursuant to
subparagraph (A), any coinsurance paid by an eligible beneficiary for the
generic drug shall be credited toward the annual deductible.
`(A) IN GENERAL- Subject to paragraph (2), if any covered outpatient
drug is provided to an eligible beneficiary in a year after the
beneficiary has met any deductible requirement under subsection (a) for
the year, the beneficiary shall be responsible for making payments for the
drug in an amount equal to the applicable percentage of the cost of the
drug.
`(B) APPLICABLE PERCENTAGE DEFINED- For purposes of subparagraph (A),
the `applicable percentage' means, with respect to any covered outpatient
drug provided to an eligible beneficiary in a year--
`(i) 50 percent to the extent the out-of-pocket expenses of the
beneficiary for such drug, when added to the out-of-pocket expenses of
the beneficiary for covered outpatient drugs previously provided in the
year, do not exceed $3,500;
`(ii) 25 percent to the extent such expenses, when so added, exceed
$3,500 but do not exceed $4,000; and
`(iii) 0 percent to the extent such expenses, when so added, would
exceed $4,000.
`(C) OUT-OF-POCKET EXPENSES DEFINED- For purposes of subparagraph (B),
the term `out-of-pocket expenses' means expenses incurred as a result of
the application of the deductible under subsection (a) and the coinsurance
required under this subsection.
`(2) REDUCTION BY ELIGIBLE ENTITY- An eligible entity may reduce the
applicable percentage that an eligible beneficiary is subject to under
paragraph (1) if the Secretary determines that such reduction--
`(A) is tied to the performance measures and other incentives
applicable to the entity pursuant to section 1860H(a); and
`(B) will not result in an increase in the expenditures made from the
Federal Supplementary Medical Insurance Trust Fund.
`(c) INFLATION ADJUSTMENT-
`(1) IN GENERAL- In the case of any calendar year beginning after 2004,
each of the dollar amounts in subsections (a)(1) and (b)(1)(B) shall be
increased by an amount equal to--
`(A) such dollar amount, multiplied by
`(B) the percentage (if any) by which the amount of average per capita
expenditures under this part in the preceding calendar year exceeds the
amount of such expenditures in 2003.
`(2) ROUNDING- If any dollar amount after being increased under
paragraph (1) is not a multiple of $5, such dollar amount shall be rounded
to the nearest multiple of $5.
`SELECTION OF ENTITIES TO PROVIDE OUTPATIENT DRUG BENEFIT
`SEC. 1860F. (a) ESTABLISHMENT OF BIDDING PROCESS-
`(1) IN GENERAL- The Secretary shall establish procedures under which
the Secretary accepts bids submitted by eligible entities and awards
contracts to such entities in order to administer and deliver the benefits
provided under this part to eligible beneficiaries in an area.
`(2) COMPETITIVE PROCEDURES- Competitive procedures (as defined in
section 4(5) of the Office of Federal Procurement Policy Act (41 U.S.C.
403(5))) shall be used to enter into contracts under this part.
`(A) IN GENERAL- Except as provided in subparagraph (B) and subject to
paragraph (2), the contract entered into between the Secretary and an
eligible entity shall require the eligible entity to provide covered
outpatient drugs on a regional basis.
`(B) PARTIAL REGIONAL BASIS-
`(i) IN GENERAL- If determined appropriate by the Secretary, the
Secretary may permit the coverage described in subparagraph (A) to be
provided on a partial regional basis.
`(ii) REQUIREMENTS- If the Secretary permits coverage pursuant to
clause (i), the Secretary shall ensure that the partial region in which
coverage is provided is--
`(I) at least the size of the commercial service area of the
eligible entity for that area; and
`(II) not smaller than a State.
`(A) IN GENERAL- In determining coverage areas under this part, the
Secretary shall--
`(i) take into account the number of eligible beneficiaries in an
area in order to encourage participation by eligible entities;
and
`(ii) ensure that there are at least 10 different coverage areas in
the United States.
`(B) NO ADMINISTRATIVE OR JUDICIAL REVIEW- The determination of
coverage areas under this part shall not be subject to administrative or
judicial review.
`(1) IN GENERAL- Each eligible entity desiring to provide covered
outpatient drugs under this part shall submit a bid to the Secretary at such
time, in such manner, and accompanied by such information as the Secretary
may reasonably require.
`(2) REQUIRED INFORMATION- The bids described in paragraph (1) shall
include--
`(A) a proposal for the estimated prices of covered outpatient drugs
and the projected annual increases in such prices, including differentials
between formulary and nonformulary prices, if applicable;
`(B) the amount that the entity will charge the Secretary for
administering and delivering the benefits under such contract;
`(C) a statement regarding whether the entity will waive the
deductible for generic drugs pursuant to section 1860E(a)(2);
`(D) a statement regarding whether the entity will reduce the
applicable coinsurance percentage pursuant to section 1860E(b)(2) and if
so, the amount of such reduction;
`(E) a detailed description of--
`(i) the risk corridors tied to performance measures and other
incentives that the entity will accept under the contract;
and
`(ii) how the entity will meet such measures and
incentives;
`(F) a detailed description of proposed contracts with local pharmacy
providers designed to ensure access, including compensation for local
pharmacists' services;
`(G) a detailed description of any ownership or shared financial
interests with other entities involved in the delivery of the benefit as
proposed;
`(H) a detailed description of the entity's estimated marketing and
advertising expenditures related to enrolling and retaining eligible
beneficiaries; and
`(I) such other information that the Secretary determines is necessary
in order to carry out this part, including information relating to the
bidding process under this part.
`(1) IN GENERAL- The Secretary shall ensure that an eligible
entity--
`(A) complies with the access requirements described in section
1860G(a)(4)(A); and
`(B) makes available to each beneficiary covered under the contract
the full scope of the benefits required under this part.
`(2) AREAS NOT COVERED BY CONTRACTS- The Secretary shall develop
procedures for the provision of covered outpatient drugs under this part to
each eligible beneficiary that resides in an area that is not covered by any
contract under this part.
`(3) BENEFICIARIES RESIDING IN DIFFERENT LOCATIONS- The Secretary shall
develop procedures to ensure that each eligible beneficiary that resides in
different areas in a year is provided the benefits under this part
throughout the entire year.
`(4) SPECIAL ATTENTION TO RURAL AND HARD-TO-SERVE AREAS-
`(A) IN GENERAL- The Secretary shall ensure that all eligible
beneficiaries have access to the full range of benefits under this part,
and shall give special attention to access, pharmacist counseling, and
delivery in rural and hard-to-serve areas (as the Secretary may define by
regulation).
`(B) SPECIAL ATTENTION DEFINED- For purposes of subparagraph (A), the
term `special attention' may include bonus payments to retail pharmacists
in rural areas, extra payments to eligible entities for the cost of rapid
delivery of pharmaceuticals, and any other actions the Secretary
determines are necessary to ensure full access to benefits under this part
by eligible beneficiaries residing in rural and hard-to-serve
areas.
`(C) GAO REPORT- Not later than 2 years after the date of enactment of
the Medicare Prescription Drug Coverage Act of 2001, the Comptroller
General of the United States shall submit to Congress a report on the
access to benefits under this part by eligible beneficiaries residing in
rural and hard-to-serve areas, together with any recommendations of the
Comptroller General regarding any additional steps the Secretary may need
to take to ensure the access of medicare beneficiaries to such
benefits.
`(e) AWARDING OF CONTRACTS-
`(1) NUMBER OF CONTRACTS- The Secretary shall, consistent with the
requirements of this part and the goal of containing costs under this title,
award in a competitive manner at least 2 contracts in an area, unless only 1
bidding entity meets the minimum standards specified under this part and by
the Secretary.
`(2) DETERMINATION- In determining which of the eligible entities that
submitted bids that meet the minimum standards specified under this part and
by the Secretary (including the terms and conditions described in section
1860G) to award a contract, the Secretary shall consider the comparative
merits of each bid, as determined on the basis of the past performance of
the entity and other relevant factors, with respect to--
`(A) how well the entity meets such minimum standards;
`(B) the amount that the entity will charge the Secretary for
administering and delivering the benefits under the contract;
`(C) the proposed prices of covered outpatient drugs and annual
increases in such prices;
`(D) the proposed risk corridors tied to performance measures and
other incentives that the entity will be subject to under the
contract;
`(E) the factors described in section 1860C(b)(2);
`(F) prior experience in administering a prescription drug benefit
program;
`(G) effectiveness in containing costs through pricing incentives and
utilization management; and
`(H) such other factors as the Secretary deems necessary to evaluate
the merits of each bid.
`(3) EXCEPTION TO CONFLICT OF INTEREST RULES- In awarding contracts
under this part, the Secretary may waive conflict of interest laws generally
applicable to Federal acquisitions (subject to such safeguards as the
Secretary may find necessary to impose) in circumstances where the Secretary
finds that such waiver--
`(A) is not inconsistent with the--
`(i) purposes of the programs under this title; or
`(ii) best interests of enrolled individuals; and
`(B) permits a sufficient level of competition for such contracts,
promotes efficiency of benefits administration, or otherwise serves the
objectives of the program under this part.
`(4) NO ADMINISTRATIVE OR JUDICIAL REVIEW- The determination of the
Secretary to award or not award a contract to an eligible entity under this
part shall not be subject to administrative or judicial review.
`(f) APPROVAL OF MARKETING MATERIAL AND APPLICATION FORMS- The provisions
of section 1851(h) shall apply to marketing material and application forms
under this part in the same manner as such provisions apply to marketing
material and application forms under part C.
`(g) DURATION OF CONTRACTS- Each contract under this part shall be for a
term of at least 2 years but not more than 5 years, as determined by the
Secretary.
`CONDITIONS FOR AWARDING CONTRACT
`SEC. 1860G. (a) IN GENERAL- The Secretary shall not award a contract to
an eligible entity under this part unless the Secretary finds that the
eligible entity agrees to comply with such terms and conditions as the
Secretary shall specify, including the following:
`(1) QUALITY AND FINANCIAL STANDARDS- The eligible entity meets the
quality and financial standards specified by the Secretary.
`(2) PROCEDURES TO ENSURE PROPER UTILIZATION, COMPLIANCE, AND AVOIDANCE
OF ADVERSE DRUG REACTIONS- The eligible entity has in place drug utilization
review procedures to ensure--
`(A) the appropriate utilization by eligible beneficiaries of the
benefits to be provided under the contract; and
`(B) the avoidance of adverse drug reactions among eligible
beneficiaries enrolled with the entity, including problems due to
therapeutic duplication, drug-disease contraindications, drug-drug
interactions (including serious interactions with nonprescription or
over-the-counter drugs), incorrect drug dosage or duration of drug
treatment, drug-allergy interactions, and clinical abuse and
misuse.
`(3) COST-EFFECTIVE PROVISION OF BENEFITS-
`(A) IN GENERAL- In providing the benefits under a contract under this
part, an eligible entity may--
`(i) employ mechanisms to provide the benefits economically,
including the use of--
`(I) formularies (pursuant to subparagraph (B));
`(II) alternative methods of distribution; and
`(III) generic drug substitution;
`(ii) use mechanisms to encourage eligible beneficiaries to select
cost-effective drugs or less costly means of receiving drugs, including
the use of pharmacy incentive programs, therapeutic interchange
programs, and disease management programs; and
`(iii) encourage pharmacy providers to--
`(I) inform beneficiaries of the differentials in price between
generic and nongeneric drug equivalents; and
`(II) provide medication therapy management programs in order to
enhance beneficiaries' understanding of the appropriate use of
medications and to reduce the risk of potential adverse events
associated with medications.
`(B) FORMULARIES- If an eligible entity uses a formulary under this
part, such formulary shall comply with standards established by the
Secretary in consultation with the Medicare Pharmacy and Therapeutics
Advisory Committee established under section 1860M. Such standards shall
require that the eligible entity--
`(i) use a pharmacy and therapeutic committee (that meets the
standards for a pharmacy and therapeutic committee established by the
Secretary in consultation with the Medicare Pharmacy and Therapeutics
Advisory Committee established under section 1860M) to develop and
implement the formulary;
`(ii) include in the formulary--
`(I) at least 1 drug from each therapeutic class (as defined by
the entity's pharmacy and therapeutic committee in accordance with
standards established by the Secretary in consultation with the
Medicare Pharmacy and Therapeutics Advisory Committee established
under section 1860M);
`(II) if there is more than 1 drug available in a therapeutic
class, at least 2 drugs from such class; and
`(III) if there are more than 2 drugs available in a therapeutic
class, at least 2 drugs from such class and a generic drug substitute
if available;
`(iii) develop procedures for the--
`(I) addition of new therapeutic classes to the
formulary;
`(II) addition of new drugs to an existing therapeutic class;
and
`(III) modification of the formulary;
`(iv) provide for coverage of otherwise covered non-formulary drugs
when recommended by a prescribing provider; and
`(v) disclose to current and prospective beneficiaries and to
providers in the service area the nature of the formulary restrictions,
including information regarding the drugs included in the formulary,
coinsurance, and any difference in the cost-sharing for different types
of drugs.
`(C) CONSTRUCTION- Nothing in this paragraph shall be construed as
precluding an eligible entity from--
`(i) requiring cost-sharing for nonformulary drugs that is higher
than the cost-sharing established in section 1860E(b), except that such
entity shall provide for coverage of a nonformulary drug at the same
cost-sharing level as a drug within the formulary if such nonformulary
drug is recommended by a prescribing provider;
`(ii) educating prescribing providers, pharmacists, and
beneficiaries about the medical and cost benefits of formulary drugs
(including generic drugs); or
`(iii) requiring prescribing providers to consider a formulary drug
prior to dispensing of a nonformulary drug, as long as such requirement
does not unduly delay the provision of the drug.
`(4) PATIENT PROTECTIONS-
`(A) ACCESS- The eligible entity ensures that the covered outpatient
drugs are accessible and convenient to eligible beneficiaries covered
under the contract, including by doing the following:
`(i) SERVICES DURING EMERGENCIES- Offering services 24 hours a day
and 7 days a week for emergencies.
`(ii) AGREEMENTS WITH PHARMACIES- Entering into participation
agreements under subsection (b) with pharmacies, that include terms
that--
`(I) secure the participation of sufficient numbers of pharmacies
to ensure convenient access (including adequate emergency access);
and
`(II) permit the participation of any pharmacy in the service area
that meets the participation requirements described in subsection
(b).
`(i) IN GENERAL- The eligible entity ensures that, in the case of an
eligible beneficiary who loses coverage under this part with such entity
under circumstances that would permit a special election period (as
established by the Secretary under section 1860B(b)), the entity will
continue to provide coverage under this part to such beneficiary until
the beneficiary enrolls and receives such coverage with another eligible
entity under this part.
`(ii) LIMITED PERIOD- In no event shall an eligible entity be
required to provide the extended coverage required under clause (i)
beyond the date which is 30 days after the coverage with such entity
would have terminated but for this subparagraph.
`(C) PROCEDURES REGARDING DENIALS OF CARE- The eligible entity has in
place procedures to ensure--
`(i) a timely internal and external review and resolution of denials
of coverage (in whole or in part) and complaints (including those
regarding the use of formularies under paragraph (3)) by eligible
beneficiaries, or by providers, pharmacists, and other individuals
acting on behalf of each such beneficiary (with the beneficiary's
consent) in accordance with requirements (as established by the
Secretary) that are comparable to such requirements for Medicare+Choice
organizations under part C; and
`(ii) that beneficiaries are provided with information regarding the
appeals procedures under this part at the time of
enrollment.
`(D) PROCEDURES REGARDING PATIENT CONFIDENTIALITY- Insofar as an
eligible entity maintains individually identifiable medical records or
other health information regarding eligible beneficiaries under a contract
entered into under this part, the entity has in place procedures
to--
`(i) safeguard the privacy of any individually identifiable
beneficiary information;
`(ii) maintain such records and information in a manner that is
accurate and timely;
`(iii) ensure timely access by such beneficiaries to such records
and information; and
`(iv) otherwise comply with applicable laws relating to patient
confidentiality.
`(E) PROCEDURES REGARDING TRANSFER OF MEDICAL RECORDS-
`(i) IN GENERAL- The eligible entity has in place procedures for the
timely transfer of records and information described in subparagraph (D)
(with respect to a beneficiary who loses coverage under this part with
the entity and enrolls with another entity under this part) to such
other entity.
`(ii) PATIENT CONFIDENTIALITY- The procedures described in clause
(i) shall comply with the patient confidentiality procedures described
in subparagraph (D).
`(F) PROCEDURES REGARDING MEDICAL ERRORS- The eligible entity has in
place procedures for working with the Secretary to deter medical errors
related to the provision of covered outpatient drugs.
`(5) PROCEDURES TO CONTROL FRAUD, ABUSE, AND WASTE- The eligible entity
has in place procedures to control fraud, abuse, and waste.
`(6) REPORTING REQUIREMENTS-
`(A) IN GENERAL- The eligible entity provides the Secretary with
reports containing information regarding the following:
`(i) The prices that the eligible entity is paying for covered
outpatient drugs.
`(ii) The prices that eligible beneficiaries enrolled with the
entity will be charged for covered outpatient drugs.
`(iii) The administrative costs of providing such
benefits.
`(iv) Utilization of such benefits.
`(v) Marketing and advertising expenditures related to enrolling and
retaining eligible beneficiaries.
`(B) TIMEFRAME FOR SUBMITTING REPORTS-
`(i) IN GENERAL- The eligible entity shall submit a report described
in subparagraph (A) to the Secretary within 3 months after the end of
each 12-month period in which the eligible entity has a contract under
this part. Such report shall contain information concerning the benefits
provided during such 12-month period.
`(ii) LAST YEAR OF CONTRACT- In the case of the last year of a
contract under this section, the Secretary may require that a report
described in subparagraph (A) be submitted 3 months prior to the end of
the contract. Such report shall contain information concerning the
benefits provided between the period covered by the most recent report
under this subparagraph and the date that a report is submitted under
this clause.
`(C) CONFIDENTIALITY OF INFORMATION-
`(i) IN GENERAL- Notwithstanding any other provision of law and
subject to clause (ii), information disclosed by an eligible entity
pursuant to subparagraph (A) is confidential and shall only be used by
the Secretary for the purposes of, and to the extent necessary, to carry
out this part.
`(ii) UTILIZATION DATA- Subject to patient confidentiality laws, the
Secretary shall make information disclosed by an eligible entity
pursuant to subparagraph (A)(iv) (regarding utilization data) available
for research purposes. The Secretary may charge a reasonable fee for
making such information available.
`(7) APPROVAL OF MARKETING MATERIAL AND APPLICATION FORMS- The eligible
entity will comply with the requirements described in section
1860F(f).
`(8) RECORDS AND AUDITS- The eligible entity maintains adequate records
related to the administration of the benefit under this part and affords the
Secretary access to such records for auditing purposes.
`(b) PHARMACY PARTICIPATION AGREEMENTS-
`(1) IN GENERAL- A pharmacy that meets the requirements of this
subsection shall be eligible to enter an agreement with an eligible entity
to furnish covered outpatient drugs and pharmacists' services to eligible
beneficiaries enrolled with such entity and residing in the service
area.
`(2) TERMS OF AGREEMENT- An agreement under this subsection shall
include the following terms and requirements:
`(A) LICENSING- The pharmacy and pharmacists shall meet (and
throughout the
contract period will continue to meet) all applicable State and local
licensing requirements.
`(B) LIMITATION ON CHARGES- Pharmacies participating under this part
shall not charge an eligible beneficiary enrolled with the eligible entity
more than--
`(i) the negotiated price for an individual drug (as reported to the
Secretary pursuant to subsection (a)(6)(A)); or
`(ii) the amount of the beneficiary's obligation (as determined in
accordance with the provisions of this part) of the negotiated price of
such drug.
`(C) PERFORMANCE STANDARDS- The pharmacy shall comply with performance
standards relating to--
`(i) measures for quality assurance, reduction of medical errors,
and compliance with the drug utilization review procedures described in
subsection (a)(2);
`(ii) systems to ensure compliance with the patient confidentiality
standards applicable under subsection (a)(4)(D); and
`(iii) other requirements as the Secretary may impose to ensure
integrity, efficiency, and the quality of the program under this
part.
`PAYMENTS
`SEC. 1860H. (a) PAYMENTS TO ELIGIBLE ENTITIES-
`(A) IN GENERAL- The Secretary shall establish procedures for making
payments to an eligible entity under a contract entered into under this
part for the administration and delivery of the benefits under this
part.
`(B) ENTITIES ONLY SUBJECT TO LIMITED RISK- Under the procedures
established under subparagraph (A), an eligible entity shall only be at
risk to the extent that the entity is at risk under paragraph
(2).
`(2) RISK CORRIDORS TIED TO PERFORMANCE MEASURES AND OTHER
INCENTIVES-
`(A) IN GENERAL- The procedures established under paragraph (1) may
include the use of--
`(i) risk corridors tied to performance measures that have been
agreed to between the eligible entity and the Secretary under the
contract; and
`(ii) any other incentives that the Secretary determines
appropriate.
`(B) PHASE-IN OF RISK CORRIDORS TIED TO PERFORMANCE MEASURES- The
Secretary may phase-in the use of risk corridors tied to performance
measures if the Secretary determines such phase-in to be
appropriate.
`(C) PAYMENTS SUBJECT TO INCENTIVES- If a contract under this part
includes the use of risk corridors tied to performance measures or other
incentives pursuant to subparagraph (A), payments to eligible entities
under such contract shall be subject to such risk corridors tied to
performance measures and other incentives.
`(3) RISK ADJUSTMENT- To the extent that eligible entities are at risk
because of the risk corridors or other incentives described in paragraph
(2)(A), the procedures established under paragraph (1) may include a
methodology for adjusting the payments made to such entities based on the
differences in actuarial risk of different enrollees being served if the
Secretary determines such adjustments to be necessary and appropriate.
`(b) SECONDARY PAYER PROVISIONS- The provisions of section 1862(b) shall
apply to the benefits provided under this part.
`EMPLOYER INCENTIVE PROGRAM FOR EMPLOYMENT-BASED RETIREE DRUG COVERAGE
`SEC. 1860I. (a) PROGRAM AUTHORITY- The Secretary is authorized to develop
and implement a program under this section called the `Employer Incentive
Program' that encourages employers and other sponsors of employment-based
health care coverage to provide adequate prescription drug benefits to retired
individuals by subsidizing, in part, the sponsor's cost of providing coverage
under qualifying plans.
`(b) SPONSOR REQUIREMENTS- In order to be eligible to receive an incentive
payment under this section with respect to coverage of an individual under a
qualified retiree prescription drug plan (as defined in subsection (f)(3)), a
sponsor shall meet the following requirements:
`(1) ASSURANCES- The sponsor shall--
`(A) annually attest, and provide such assurances as the Secretary may
require, that the coverage offered by the sponsor is a qualified retiree
prescription drug plan, and will remain such a plan for the duration of
the sponsor's participation in the program under this section;
and
`(B) guarantee that it will give notice to the Secretary and covered
retirees--
`(i) at least 120 days before terminating its plan; and
`(ii) immediately upon determining that the actuarial value of the
prescription drug benefit under the plan falls below the actuarial value
of the outpatient prescription drug benefit under this part.
`(2) BENEFICIARY INFORMATION- The sponsor shall report to the Secretary,
for each calendar quarter for which it seeks an incentive payment under this
section, the names and social security numbers of all retirees (and their
spouses and dependents) covered under such plan during such quarter and the
dates (if less than the full quarter) during which each such individual was
covered.
`(3) AUDITS- The sponsor and the employment-based retiree health
coverage plan seeking incentive payments under this section shall agree to
maintain, and to afford the Secretary access to, such records as the
Secretary may require for purposes of audits and other oversight activities
necessary to ensure the adequacy of prescription drug coverage, the
accuracy of incentive payments made, and such other matters as may be
appropriate.
`(4) OTHER REQUIREMENTS- The sponsor shall provide such other
information, and comply with such other requirements, as the Secretary may
find necessary to administer the program under this section.
`(1) IN GENERAL- A sponsor that meets the requirements of subsection (b)
with respect to a quarter in a calendar year shall be entitled to have
payment made by the Secretary on a quarterly basis (to the sponsor or, at
the sponsor's direction, to the appropriate employment-based health plan) of
an incentive payment, in the amount determined in paragraph (2), for each
retired individual (or spouse) who--
`(A) was covered under the sponsor's qualified retiree prescription
drug plan during such quarter; and
`(B) was eligible for, but was not enrolled in, the outpatient
prescription drug benefit program under this part.
`(2) AMOUNT OF INCENTIVE- The payment under this section with respect to
each individual described in paragraph (1) for a month shall be equal to 2/3
of the monthly premium amount payable by an eligible beneficiary enrolled
under this part, as set for the calendar year pursuant to section
1860D(a)(2).
`(3) PAYMENT DATE- The incentive under this section with respect to a
calendar quarter shall be payable as of the end of the next succeeding
calendar quarter.
`(d) CIVIL MONEY PENALTIES- A sponsor, health plan, or other entity that
the Secretary determines has, directly or through its agent, provided
information in connection with a request for an incentive payment under this
section that the entity knew or should have known to be false shall be subject
to a civil monetary penalty in an amount up to 3 times the total incentive
amounts under subsection (c) that were paid (or would have been payable) on
the basis of such information.
`(e) DEFINITIONS- In this section:
`(1) EMPLOYMENT-BASED RETIREE HEALTH COVERAGE- The term
`employment-based retiree health coverage' means health insurance or other
coverage of health care costs for retired individuals (or for such
individuals and their spouses and dependents) based on their status as
former employees or labor union members.
`(2) EMPLOYER- The term `employer' has the meaning given the term in
section 3(5) of the Employee Retirement Income Security Act of 1974 (except
that such term shall include only employers of 2 or more employees).
`(3) QUALIFIED RETIREE PRESCRIPTION DRUG PLAN- The term `qualified
retiree prescription drug plan' means health insurance coverage included in
employment-based retiree health coverage that--
`(A) provides coverage of the cost of prescription drugs whose
actuarial value (as defined by the Secretary) to each retired beneficiary
equals or exceeds the actuarial value of the benefits provided to an
individual enrolled in the outpatient prescription drug benefit program
under this part; and
`(B) does not deny, limit, or condition the coverage or provision of
prescription drug benefits for retired individuals based on age or any
health status-related factor described in section 2702(a)(1) of the Public
Health Service Act.
`(4) SPONSOR- The term `sponsor' has the meaning given the term `plan
sponsor' in section 3(16)(B) of the Employer Retirement Income Security Act
of 1974.
`(f) AUTHORIZATION OF APPROPRIATIONS- There are authorized to be
appropriated from time to time, out of any moneys in the Treasury not
otherwise appropriated, such sums as may be necessary to carry out the program
under this section.
`PROCEDURES FOR PARTIAL YEAR IMPLEMENTATION
`SEC. 1860J. If the Secretary first implements the program under this part
on a day other that January 1 of a year, the Secretary shall establish
procedures for implementing the program during the period between the date of
implementation and December 31 of such year, including procedures--
`(1) for prorating premiums, deductibles, and coinsurance under the
program during such period; and
`(2) relating to requirements and payments under the Medicare+Choice
program during such period.
`APPROPRIATIONS
`SEC. 1860K. There are authorized to be appropriated from time to time,
out of any moneys in the Treasury not otherwise appropriated, to the Federal
Supplementary Medical Insurance Trust Fund established under section 1841, an
amount equal to the amount by which the benefits and administrative costs of
providing the benefits under this part exceed the premiums collected under
section 1860D.
`Subpart 2--Medicare Pharmacy and Therapeutics (P&T) Advisory
Committee
`MEDICARE PHARMACY AND THERAPEUTICS (P&T) ADVISORY COMMITTEE
`SEC. 1860M. (a) ESTABLISHMENT OF COMMITTEE- There is established a
Medicare Pharmacy and Therapeutics Advisory Committee (in this section
referred to as the `Committee').
`(b) FUNCTIONS OF COMMITTEE- On and after January 1, 2002, the Committee
shall advise the Secretary on policies related to--
`(1) the development of guidelines for the implementation and
administration of the outpatient prescription drug benefit program under
this part; and
`(2) the development of--
`(A) standards for a pharmacy and therapeutics committee required of
eligible entities under section 1860G(a)(3)(B)(i);
`(i) defining therapeutic classes;
`(ii) adding new therapeutic classes to a formulary;
`(iii) adding new drugs to a therapeutic class within a formulary;
and
`(iv) when and how often a formulary should be modified;
`(C) procedures to evaluate the bids submitted by eligible entities
under this part; and
`(D) procedures to ensure that eligible entities with a contract under
this part are in compliance with the requirements under this
part.
`(c) STRUCTURE AND MEMBERSHIP OF THE COMMITTEE-
`(1) STRUCTURE- The Committee shall be composed of 19 members who shall
be appointed by the Secretary.
`(A) IN GENERAL- The members of the Committee shall be chosen on the
basis of their integrity, impartiality, and good judgment, and shall be
individuals who are, by reason of their education, experience, and
attainments, exceptionally qualified to perform the duties of members of
the Committee.
`(B) SPECIFIC MEMBERS- Of the members appointed under paragraph
(1)--
`(i) eleven shall be chosen to represent physicians;
`(ii) four shall be chosen to represent pharmacists;
`(iii) one shall be chosen to represent the Health Care Financing
Administration;
`(iv) two shall be chosen to represent actuaries and
pharmacoeconomists; and
`(v) one shall be chosen to represent emerging drug
technologies.
`(d) TERMS OF APPOINTMENT- Each member of the Committee shall serve for a
term determined appropriate by the Secretary. The terms of service of the
members initially appointed shall begin on January 1, 2002.
`(e) CHAIRMAN- The Secretary shall designate a member of the Committee as
Chairman. The term as Chairman shall be for a 1-year period.
`(f) COMPENSATION AND TRAVEL EXPENSES-
`(1) COMPENSATION OF MEMBERS- Each member of the Committee who is not an
officer or employee of the Federal Government shall be compensated at a rate
equal to the daily equivalent of the annual rate of basic pay prescribed for
level IV of the Executive Schedule under section 5315 of title 5, United
States Code, for each day (including travel time) during which such member
is engaged in the performance of the duties of the Committee. All members of
the Committee who are officers or employees of the United States shall serve
without compensation in addition to that received for their services as
officers or employees of the United States.
`(2) TRAVEL EXPENSES- The members of the Committee shall be allowed
travel expenses, including per diem in lieu of subsistence, at rates
authorized for employees of agencies under subchapter I of chapter 57 of
title 5, United States Code, while away from their homes or regular places
of business in the performance of services for the Committee.
`(g) OPERATION OF THE COMMITTEE-
`(1) MEETINGS- The Committee shall meet at the call of the Chairman
(after consultation with the other members of the Committee) not less often
than quarterly to consider a specific agenda of issues, as determined by the
Chairman after such consultation.
`(2) QUORUM- Ten members of the Committee shall constitute a quorum for
purposes of conducting business.
`(h) FEDERAL ADVISORY COMMITTEE ACT- Section 14 of the Federal Advisory
Committee Act (5 U.S.C. App.) shall not apply to the Committee.
`(i) TRANSFER OF PERSONNEL, RESOURCES, AND ASSETS- For purposes of
carrying out its duties, the Secretary and the Committee may provide for the
transfer to the Committee of such civil service personnel in the employ of the
Department of Health and Human Services, and such resources and assets of the
Department used in carrying out this title, as the Committee requires.
`(j) AUTHORIZATION OF APPROPRIATIONS- There are authorized to be
appropriated such sums as may be necessary to carry out the purposes of this
section.'.
(b) EXCLUSIONS FROM COVERAGE-
(1) APPLICATION TO PART D- Section 1862(a) of the Social Security Act
(42 U.S.C. 1395y(a)) is amended in the matter preceding paragraph (1) by
striking `part A or part B' and inserting `part A, B, or D'.
(2) PRESCRIPTION DRUGS NOT EXCLUDED FROM COVERAGE IF APPROPRIATELY
PRESCRIBED- Section 1862(a)(1) of the Social Security Act (42 U.S.C.
1395y(a)(1)) is amended--
(A) in subparagraph (H), by striking `and' at the end;
(B) in subparagraph (I), by striking the semicolon at the end and
inserting `, and'; and
(C) by adding at the end the following new subparagraph:
`(J) in the case of prescription drugs covered under part D, which are
not prescribed in accordance with such part;'.
(c) CONFORMING REFERENCES TO PREVIOUS PART D-
(1) IN GENERAL- Any reference in law (in effect before the date of
enactment of this Act) to part D of title XVIII of the Social Security Act
is deemed a reference to part E of such title (as in effect after such
date).
(2) SECRETARIAL SUBMISSION OF LEGISLATIVE PROPOSAL- Not later than 6
months after the date of enactment of this Act, the Secretary of Health and
Human Services shall submit to the appropriate committees of Congress a
legislative proposal providing for such technical and conforming amendments
in the law as are required by the provisions of this Act.
SEC. 4. PART D BENEFITS UNDER MEDICARE+CHOICE PLANS.
(a) ELIGIBILITY, ELECTION, AND ENROLLMENT- Section 1851 of the Social
Security Act (42 U.S.C. 1395w-21) is amended--
(1) in subsection (a)(1)(A), by striking `parts A and B' and inserting
`parts A, B, and D'; and
(2) in subsection (i)(1), by striking `parts A and B' and inserting
`parts A, B, and D'.
(b) VOLUNTARY BENEFICIARY ENROLLMENT FOR DRUG COVERAGE- Section
1852(a)(1)(A) of such Act (42 U.S.C. 1395w-22(a)(1)(A)) is amended by
inserting `(and under part D to individuals also enrolled under that part)'
after `parts A and B'.
(c) ACCESS TO SERVICES- Section 1852(d)(1) of such Act (42 U.S.C.
1395w-22(d)(1)) is amended--
(1) in subparagraph (D), by striking `and' at the end;
(2) in subparagraph (E), by striking the period at the end and inserting
`; and'; and
(3) by adding at the end the following new subparagraph:
`(F) in the case of covered outpatient drugs provided to individuals
enrolled under part D (as defined in section 1860(1)), the organization
complies with the access requirements applicable under part D.'.
(d) PAYMENTS TO ORGANIZATIONS- Section 1853(a)(1)(A) of such Act (42
U.S.C. 1395w-23(a)(1)(A)) is amended--
(1) by inserting `determined separately for the benefits under parts A
and B and under part D (for individuals enrolled under that part)' after `as
calculated under subsection (c)';
(2) by striking `that area, adjusted for such risk factors' and
inserting `that area. In the case of payment for the benefits under parts A
and B, such payment shall be adjusted for such risk factors as'; and
(3) by inserting before the last sentence the following: `In the case of
the payments for the benefits under part D, such payment shall initially be
adjusted for the risk factors of each enrollee as the Secretary determines
to be feasible and appropriate to ensure actuarial equivalence. By 2006, the
adjustments to payments for benefits under part D shall be for the same risk
factors used to adjust payments for the benefits under parts A and
B.'.
(e) CALCULATION OF ANNUAL MEDICARE+CHOICE CAPITATION RATES- Section
1853(c) of such Act (42 U.S.C. 1395w-23(c)) is amended--
(1) in paragraph (1), in the matter preceding subparagraph (A), by
inserting `for benefits under parts A and B' after `capitation rate';
and
(2) by adding at the end the following new paragraph:
`(8) PAYMENT FOR PART D BENEFITS- The Secretary shall determine a
capitation rate for part D benefits (for individuals enrolled under such
part) as follows:
`(A) DRUGS DISPENSED BEFORE 2004- In the case of prescription drugs
dispensed on or after the date that is 1 year after the date of enactment
of the Medicare Prescription Drug Coverage Act of 2001 and before January
1, 2004, the capitation rate shall be based on the projected national per
capita costs for prescription drug benefits under part D and associated
claims processing costs for beneficiaries enrolled under part D and not
enrolled with a Medicare+Choice organization under this part.
`(B) DRUGS DISPENSED IN SUBSEQUENT YEARS- In the case of prescription
drugs dispensed in 2004 or a subsequent year, the capitation rate shall be
equal to the capitation rate for the preceding year increased by the
Secretary's estimate of the projected per capita rate of growth in
expenditures under this title for an individual enrolled under part D for
such subsequent year.'.
(f) LIMITATION ON ENROLLEE LIABILITY- Section 1854(e) of such Act (42
U.S.C. 1395w-24(e)) is amended by adding at the end the following new
paragraph:
`(5) SPECIAL RULE FOR PART D BENEFITS- With respect to outpatient
prescription drug benefits under part D, a Medicare+Choice organization may
not require that an enrollee pay a deductible or a coinsurance percentage
that exceeds the deductible or coinsurance percentage applicable for such
benefits for an eligible beneficiary under part D.'.
(g) REQUIREMENT FOR ADDITIONAL BENEFITS- Section 1854(f)(1) of such Act
(42 U.S.C. 1395w-24(f)(1)) is amended by adding at the end the following new
sentence: `Such determination shall be made separately for the benefits under
parts A and B and for prescription drug benefits under part D.'.
(h) EFFECTIVE DATE- The amendments made by this section shall apply to
items and services provided under a Medicare+Choice plan on or after the date
that is 1 year after the date of enactment of this Act.
SEC. 5. EXCLUSION OF PART D COSTS FROM DETERMINATION OF PART B MONTHLY
PREMIUM.
Section 1839(g) of the Social Security Act (42 U.S.C. 1395r(g)) is
amended--
(1) by striking `attributable to the application of section' and
inserting `attributable to--
`(1) the application of section';
(2) by striking the period and inserting `; and'; and
(3) by adding at the end the following new paragraph:
`(2) the program under part D providing payment for covered outpatient
drugs (including costs associated with making payments to employers and
other sponsors of employment-based health care coverage under the Employer
Incentive Program under section 1860I).'.
SEC. 6. ADDITIONAL ASSISTANCE FOR LOW-INCOME BENEFICIARIES.
(a) INCLUSION IN MEDICARE COST-SHARING- Section 1905(p)(3) of the Social
Security Act (42 U.S.C. 1396d(p)(3)) is amended--
(1) in subparagraph (A)--
(A) in clause (i), by striking `and' at the end;
(B) in clause (ii), by inserting `and' at the end; and
(C) by adding at the end the following new clause:
`(iii) premiums under section 1860D.';
(2) in subparagraph (B), by striking `section 1813' and inserting
`sections 1813 and 1860E(b)'; and
(3) in subparagraph (C), by striking `section 1813 and section 1833(b)'
and inserting `sections 1813, 1833(b), and 1860E(a)'.
(b) EXPANSION OF MEDICAL ASSISTANCE- Section 1902(a)(10)(E) of the Social
Security Act (42 U.S.C. 1396a(a)(10)(E)) is amended--
(A) by striking `section 1905(p)(3)(A)(ii)' and inserting `clauses
(ii) and (iii) of section 1905(p)(3)(A), for the coinsurance described in
section 1860E(b), and for the deductible described in section 1860E(a)';
and
(B) by striking `and' at the end;
(2) by redesignating clause (iv) as clause (vi); and
(3) by inserting after clause (iii) the following new clauses:
`(iv) for making medical assistance available for Medicare
cost-sharing described in section 1905(p)(3)(A)(iii), for the coinsurance
described in section 1860E(b), and for the deductible described in section
1860E(a) for individuals who would be qualified Medicare beneficiaries
described in section 1905(p)(1) but for the fact that their income exceeds
120 percent but does not exceed 135 percent of such official poverty line
for a family of the size involved;
`(v) for making medical assistance available for Medicare cost-sharing
described in section 1905(p)(3)(A)(iii) on a linear sliding scale based on
the income of such individuals for individuals who would be qualified
Medicare beneficiaries described in section 1905(p)(1) but for the fact
that their income exceeds 135 percent but does not exceed 175 percent of
such official poverty line for a family of the size involved;
and'.
(c) NONAPPLICABILITY OF RESOURCE REQUIREMENTS TO MEDICARE PART D
COST-SHARING- Section 1905(p)(1) of the Social Security Act (42 U.S.C.
1396d(p)(1)) is amended by adding at the end the following flush sentence:
`In determining if an individual is a qualified medicare beneficiary under
this paragraph, subparagraph (C) shall not be applied for purposes of
providing the individual with medicare cost-sharing that consists of premiums
under section 1860D, coinsurance described in section 1860E(b), or deductibles
described in section 1860E(a).'.
(d) NONAPPLICABILITY OF PAYMENT DIFFERENTIAL REQUIREMENTS TO MEDICARE PART
D COST-SHARING- Section 1902(n)(2) of the Social Security Act (42 U.S.C.
1396a(n)(2)) is amended by adding at the end the following new sentence: `The
preceding sentence shall not apply to coinsurance described in section
1860E(b) or deductibles described in section 1860E(a).'.
(e) 100 PERCENT FEDERAL MEDICAL ASSISTANCE PERCENTAGE- The first sentence
of section 1905(b) of the Social Security Act (42 U.S.C. 1396d(b)) is
amended--
(1) by striking `and' before `(3)'; and
(2) by inserting before the period at the end the following: `, and (4)
the Federal medical assistance percentage shall be 100 percent with respect
to medical assistance provided under clauses (iv) and (v) of section
1902(a)(10)(E)'.
(f) TREATMENT OF TERRITORIES- Section 1108(g) of such Act (42 U.S.C.
1308(g)) is amended by adding at the end the following new paragraph:
`(3) Notwithstanding the preceding provisions of this subsection, with
respect to the first fiscal quarter that begins on or after the date that is 1
year after the date of enactment of the Medicare Prescription Drug Coverage
Act of 2001 and any fiscal year thereafter, the amount otherwise determined
under this subsection (and subsection (f)) for the fiscal year for a
Commonwealth or territory shall be increased by the ratio (as estimated by the
Secretary) of--
`(A) the aggregate amount of payments made to the 50 States and the
District of Columbia for the fiscal year under title XIX that are
attributable to making medical assistance available for individuals
described in clauses (i), (iii), (iv), and (v) of section 1902(a)(10)(E) for
payment of Medicare cost-sharing that consists of premiums under section
1860D, coinsurance described in section 1860E(b), or deductibles described
in section 1860E(a); to
`(B) the aggregate amount of total payments made to such States and
District for the fiscal year under such title.'.
(g) CONFORMING AMENDMENTS- Section 1933 of the Social Security Act (42
U.S.C. 1396u-3) is amended--
(1) in subsection (a), by striking `section 1902(a)(10)(E)(iv)' and
inserting `section 1902(a)(10)(E)(vi)';
(2) in subsection (c)(2)(A)--
(A) in clause (i), by striking `section 1902(a)(10)(E)(iv)(I)' and
inserting `section 1902(a)(10)(E)(vi)(I)'; and
(B) in clause (ii), by striking `section 1902(a)(10)(E)(iv)(II)' and
inserting `section 1902(a)(10)(E)(vi)(II)';
(3) in subsection (d), by striking `section 1902(a)(10)(E)(iv)' and
inserting `section 1902(a)(10)(E)(vi)'; and
(4) in subsection (e), by striking `section 1902(a)(10)(E)(iv)' and
inserting `section 1902(a)(10)(E)(vi)'.
(h) EFFECTIVE DATE- The amendments made by this section shall apply for
medical assistance provided under section 1902(a)(10)(E) of the Social
Security Act (42 U.S.C. 1396a(a)(10)(E)) on and after the date that is 1 year
after the date of enactment of this Act.
SEC. 7. MEDIGAP REVISIONS.
Section 1882 of the Social Security Act (42 U.S.C. 1395ss) is amended by
adding at the end the following new subsection:
`(v) MODERNIZED BENEFIT PACKAGES FOR MEDICARE SUPPLEMENTAL POLICIES-
`(1) PROMULGATION OF MODEL REGULATION-
`(A) NAIC MODEL REGULATION- If, within 6 months after the date of
enactment of the Medicare Prescription Drug Coverage Act of 2001, the
National Association of Insurance Commissioners (in this subsection
referred to as the `NAIC') changes the 1991 NAIC Model Regulation
(described in subsection (p)) to revise the benefit packages classified as
`H', `I', and `J' under the standards established by subsection (p)(2)
(including the benefit package classified as `J' with a high deductible
feature, as described in subsection (p)(11)) so that--
`(i) the coverage for outpatient prescription drugs available under
such benefit packages is replaced with coverage for outpatient
prescription drugs that compliments but does not duplicate the benefits
for outpatient prescription drugs that beneficiaries are otherwise
entitled to under this title;
`(ii) the revised benefit packages provide a range of coverage
options for outpatient prescription drugs for beneficiaries, but do not
provide coverage for--
`(I) the deductible under section 1860E(a); or
`(II) more than 90 percent of the coinsurance applicable to an
individual under section 1860E(b);
`(iii) uniform language and definitions are used with respect to
such revised benefits;
`(iv) uniform format is used in the policy with respect to such
revised benefits; and
`(v) such revised standards meet any additional requirements imposed
by the Medicare Prescription Drug Coverage Act of 2001;
subsection (g)(2)(A) shall be applied in each State, effective for
policies issued to policy holders on and after the date that is 1 year
after the date of enactment of the Medicare Prescription Drug Coverage Act
of 2001, as if the reference to the Model Regulation adopted on June 6,
1979, were a reference to the 1991 NAIC Model Regulation as changed under
this subparagraph (such changed regulation referred to in this section as
the `2002 NAIC Model Regulation').
`(B) REGULATION BY THE SECRETARY- If the NAIC does not make the
changes in the 1991 NAIC Model Regulation within the 6-month period
specified in subparagraph (A), the Secretary shall promulgate, not later
than 6 months after the end of such period, a regulation and subsection
(g)(2)(A) shall be applied in each State, effective for policies issued to
policy holders on and after the date that is 1 year after the date of
enactment of the Medicare Prescription Drug Coverage Act of 2001, as if
the reference to the Model Regulation adopted on June 6, 1979, were a
reference to the 1991 NAIC Model Regulation as changed by the Secretary
under this subparagraph (such changed regulation referred to in this
section as the `2002 Federal Regulation').
`(C) CONSULTATION WITH WORKING GROUP- In promulgating standards under
this paragraph, the NAIC or Secretary shall consult with a working group
similar to the working group described in subsection (p)(1)(D).
`(D) MODIFICATION OF STANDARDS IF MEDICARE BENEFITS CHANGE- If
benefits (including deductibles and coinsurance) under part D of this
title are changed and the Secretary determines, in consultation with the
NAIC, that changes in the 2002 NAIC Model Regulation or 2002 Federal
Regulation are needed to reflect such changes, the preceding provisions of
this paragraph shall apply to the modification of standards previously
established in the same manner as they applied to the original
establishment of such standards.
`(2) CONSTRUCTION OF BENEFITS IN OTHER MEDICARE SUPPLEMENTAL POLICIES-
Nothing in the benefit packages classified as `A' through `G' under the
standards established by subsection (p)(2) (including the benefit package
classified as `F' with a high deductible feature, as described in subsection
(p)(11)) shall be construed as providing coverage for benefits for which
payment may be made under part D.
`(3) APPLICATION OF PROVISIONS AND CONFORMING REFERENCES-
`(A) APPLICATION OF PROVISIONS- The provisions of paragraphs (4)
through (10) of subsection (p) shall apply under this section, except
that--
`(i) any reference to the model regulation applicable under that
subsection shall be deemed to be a reference to the applicable 2002 NAIC
Model Regulation or 2002 Federal Regulation; and
`(ii) any reference to a date under such paragraphs of subsection
(p) shall be deemed to be a reference to the appropriate date under this
subsection.
`(B) OTHER REFERENCES- Any reference to a provision of subsection (p)
or a date applicable under such subsection shall also be considered to be
a reference to the appropriate provision or date under this
subsection.'.
SEC. 8. COMPREHENSIVE IMMUNOSUPPRESSIVE DRUG COVERAGE FOR TRANSPLANT
PATIENTS.
(a) IN GENERAL- Section 1861(s)(2)(J) of the Social Security Act (42
U.S.C. 1395x(s)(2)(J)), as amended by section 113(a) of the Medicare,
Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (as
enacted into law by section 1(a)(6) of Public Law 106-554), is amended by
striking `, to an individual who receives' and all that follows before the
semicolon at the end and inserting `to an individual who has received an organ
transplant'.
(b) EFFECTIVE DATE- The amendment made by subsection (a) shall apply to
drugs furnished on or after the date of enactment of this Act.
SEC. 9. HHS STUDIES AND REPORT TO CONGRESS REGARDING OUTPATIENT PRESCRIPTION
DRUG BENEFIT PROGRAM.
(a) STUDIES- The Secretary of Health and Human Services shall conduct a
study on the following:
(1) WAIVER OR REDUCTION OF LATE ENROLLMENT PENALTY- The feasibility and
advisability of establishing an annual open enrollment period under the
outpatient prescription drug benefit program under part D of title XVIII of
the Social Security Act (as added by section 3) in which the late enrollment
penalty under section 1860B(a)(2)(A) of the Social Security Act (as so
added) would be reduced or would not be applied. Such study shall include a
projection of the costs if open enrollment was allowed with a reduced
penalty or without a penalty.
(2) UNIFORM FORMAT FOR PHARMACY BENEFIT CARDS- The feasibility and
advisability of establishing a uniform format for pharmacy benefit cards
provided to beneficiaries by eligible entities under such outpatient
prescription drug benefit program.
(3) DEVELOPMENT OF SYSTEMS TO ELECTRONICALLY TRANSFER PRESCRIPTIONS- The
feasibility and advisability of developing systems to electronically
transfer prescriptions under such outpatient prescription drug benefit
program from the prescriber to the pharmacist.
(b) REPORT- Not later than 9 months after the date of enactment of this
Act, the Secretary of Health and Human Services shall submit to Congress a
report on the results of the studies conducted under subsection (a), together
with any recommendations for legislation that the Secretary determines to be
appropriate as a result of such studies.
SEC. 10. GAO STUDY AND BIENNIAL REPORTS ON COMPETITION AND SAVINGS.
(a) ONGOING STUDY- The Comptroller General of the United States shall
conduct an ongoing study and analysis of the outpatient prescription drug
benefit program under part D of title XVIII of the Social Security Act (as
added by section 3), including an analysis of--
(1) the extent to which the competitive bidding process under such
program fosters maximum competition and efficiency; and
(2) the savings to the medicare program resulting from such outpatient
prescription drug benefit program, including the reduction in the number or
length of hospital visits.
(b) INITIAL REPORT ON COMPETITIVE BIDDING PROCESS- Not later than 9 months
after the date of enactment of this Act, the Comptroller General shall submit
to Congress a report on the extent to which the competitive bidding process
under the outpatient prescription drug benefit program under part D of title
XVIII of the Social Security Act (as added by section 3) is expected to foster
maximum competition and efficiency.
(c) BIENNIAL REPORTS- Not later than January 1, 2004, and biennially
thereafter, the Comptroller General of the United States shall submit to
Congress a report on the results of the study conducted under subsection (a),
together with any recommendations for legislation that the Comptroller General
determines to be appropriate as a result of such study.
SEC. 11. MEDPAC STUDY AND ANNUAL REPORTS ON THE PHARMACEUTICAL MARKET,
PHARMACIES, AND BENEFICIARY ACCESS.
(a) ONGOING STUDY- The Medicare Payment Advisory Commission shall conduct
an ongoing study and analysis of the outpatient prescription drug benefit
program under part D of title XVIII of the Social Security Act (as added by
section 3), including an analysis of the impact of such program on--
(1) the pharmaceutical market, including costs and pricing of
pharmaceuticals, beneficiary access to such pharmaceuticals, and trends in
research and development;
(2) franchise, independent, and rural pharmacies; and
(3) beneficiary access to outpatient prescription drugs, including an
assessment of--
(A) out-of-pocket spending;
(B) generic and brand-name utilization; and
(C) pharmacists' services.
(b) REPORT- Not later than January 1, 2004, and annually thereafter, the
Medicare Payment Advisory Commission shall submit to Congress a report on the
results of the study conducted under subsection (a), together with any
recommendations for legislation that such Commission determines to be
appropriate as a result of such study.
SEC. 12. APPROPRIATIONS.
In addition to amounts otherwise appropriated to the Secretary of Health
and Human Services, there are authorized to be appropriated to the Secretary
for fiscal year 2002 and each subsequent fiscal year such sums as may be
necessary to administer the outpatient prescription drug benefit program under
part D of title XVIII of the Social Security Act (as added by section 3).
END